Brochure More information from http://www.researchandmarkets.com/reports/3175853/

Global Inflammatory Bowel Disease Market 2015-2019 Description:

About Inflammatory Bowel Disease Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn's disease causes inflammation of the lining of the GI tract. The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management. The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-a inhibitors. The analysts forecast the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019. Covered in this Report This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Inflammatory Bowel Disease market. The vendor landscape includes an analysis of the major vendors, along with the competitive performances of their portfolios. In addition, the report discusses the major drivers, challenges and trends influencing the market. In addition, late-stage pipeline molecules developed for the treatment of inflammatory bowel disease are discussed. The report, Global Inflammatory Bowel Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the landscape of the Global Inflammatory Bowel Disease market and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions - Americas - APAC - EMEA Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals Market drivers - Increase in Instances of Inflammatory Bowel Disease - For a full, detailed list, view our report Market challenges - High Cost of Drugs - For a full, detailed list, view our report Market trends - Dominance of Market by Biologics - For a full, detailed list, view our report Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key Market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors?

Contents:

01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market overview 03.2 Product offerings 04. Market Research Methodology 04.1 Market research process 04.2 Research methodology 05. Introduction 06. Disease Overview: Crohn's Disease 06.1 Understanding the disease 06.2 Etiology

06.2.1 Autoimmune reaction 06.2.2 Genes 06.2.3 Environment 06.3 Stages of Crohn's disease 06.4 Epidemiology 06.4.1 Worldwide prevalence of Crohn's disease 06.4.2 US 06.4.3 UK 06.5 Symptoms 06.5.1 Diarrhea 06.5.2 Fever and fatigue 06.5.3 Abdominal pain and cramping 06.5.4 Perianal disease and blood in stool 06.5.5 Reduced appetite and weight loss 06.6 Diagnosis and testing 06.6.1 Early tests and exams 06.6.2 Endoscopy and biopsy 06.6.3 Chromoendoscopy 06.6.4 Small intestinal imaging 06.7 Treatment 06.7.1 Medication 06.7.2 Diet and nutrition 06.7.3 Surgery 07. Disease Overview: Ulcerative Colitis 07.1 Understanding the disease 07.2 Etiology 07.2.1 Autoimmune reaction 07.2.2 Genetics 07.2.3 Environmental factors 07.3 Prognosis 07.4 Epidemiology 07.4.1 Global 07.4.2 UK 07.4.3 US 07.5 Symptoms 07.6 Diagnosis and testing 07.7 Treatment 07.7.1 Medical treatment options 07.7.2 Surgical procedures 08. Pipeline Portfolio 08.1 Crohn's disease pipeline landscape 08.1.1 Some emerging therapeutic options 08.2 Ulcerative colitis pipeline landscape 09. Market Landscape 09.1 Global inflammatory bowel disease market 09.2 Market size and forecast 09.3 Inflammatory bowel disease market in US 09.3.1 Market size and forecast 09.4 Inflammatory bowel disease market in EU 09.4.1 Market size and forecast 09.5 Inflammatory bowel disease market in Japan 09.5.1 Market size and forecast 09.6 Five forces analysis 10. Market Segmentation by Type of Disease 10.1 Crohn's disease 10.2 Ulcerative colitis 11. Global Crohn's Disease Market 11.1 Market size and forecast 11.2 Crohn's disease market in US 11.2.1 Market size and forecast 11.3 Crohn's disease market in Japan 11.3.1 Market size and forecast 12. Global Ulcerative Colitis Market

12.1 Market size and forecast 13. Market Segmentation by Drug Class 14. Market Segmentation by Type of Molecule 14.1 Biologics 14.2 Small molecules 15. Market Segmentation by Dosage Form 15.1 Solid 15.2 Liquid 16. Market Segmentation by Route of Administration 16.1 Oral 16.2 Parenteral 17. Geographical Segmentation 17.1 Segmentation of global inflammatory market by geography 17.2 Segmentation of global Crohn's disease and ulcerative colitis markets by geography 17.3 Segmentation of global Crohn's disease market by geography 17.4 Segmentation of global ulcerative colitis market by geography 18. Key Leading Countries 18.1 Key leading countries 2014 18.2 Key leading countries 2019 18.3 US 18.4 Japan 19. Buying Criteria 20. Market Growth Drivers 21. Drivers and their Impact 22. Market Challenges 23. Impact of Drivers and Challenges 24. Market Trends 25. Trends and their Impact 26. Vendor Landscape 26.1 Competitive scenario 26.1.1 Key news 26.1.2 Mergers and acquisitions 26.2 Market share analysis 2014 26.2.1 Competitive assessment of top drugs for inflammatory bowel disease 26.2.2 AbbVie 26.2.3 Janssen Pharmaceuticals 26.2.4 Merck 26.2.5 Biogen Idec 26.2.6 UCB 26.2.7 Shire 26.3 Other and future prominent vendors 27. Key Vendor Analysis 27.1 AbbVie 27.1.1 Key facts 27.1.2 Business overview 27.1.3 Product segmentation by revenue 2013 27.1.4 Product segmentation by revenue 2012 and 2013 27.1.5 Sales by geography 27.1.6 Business strategy 27.1.7 Key developments 27.1.8 SWOT analysis 27.2 Biogen Idec 27.2.1 Key facts 27.2.2 Business overview 27.2.3 Business segmentation by revenue 2013 27.2.4 Geographical segmentation by revenue 2013 27.2.5 Business strategy 27.2.6 Key developments 27.2.7 SWOT analysis 27.3 Janssen Pharmaceuticals 27.3.1 Key facts 27.3.2 Business overview 27.3.3 Recent developments

27.3.4 SWOT analysis 27.4 Merck 27.4.1 Key facts 27.4.2 Business overview 27.4.3 Business segmentation by revenue 2013 27.4.4 Business segmentation by revenue 2012 and 2013 27.4.5 Sales by geography 27.4.6 Business strategy 27.4.7 Key developments 27.4.8 SWOT analysis 27.5 Shire 27.5.1 Key facts 27.5.2 Business overview 27.5.3 Geographical segmentation by revenue 2013 27.5.4 Business strategy 27.5.5 Recent developments 27.5.6 SWOT analysis 27.6 UCB 27.6.1 Key facts 27.6.2 Business overview 27.6.3 Product segmentation by revenue 2013 27.6.4 Product segmentation by revenue 2012 and 2013 27.6.5 Geographical segmentation by revenue 2013 27.6.6 Business strategy 27.6.7 Recent developments 27.6.8 SWOT analysis 28. Other Reports in this Series List of Exhibits: Exhibit 1: Market research methodology Exhibit 2: Challenges and drivers of global inflammatory bowel disease market Exhibit 3: Overview of Crohn's disease Exhibit 4: Classification of Crohn's disease Exhibit 5: Expected number of global Crohn's disease cases 2015-2022 Exhibit 6: Global variation in incidence rates for Crohn's disease in 2012 (in %) Exhibit 7: Prevalence of Crohn's disease in US Exhibit 8: Incidence of Crohn's disease in US Exhibit 9: Symptoms of Crohn's disease Exhibit 10: Crohn's disease: diagnosis and testing Exhibit 11: Crohn's disease: treatment Exhibit 12: Treatment landscape for Crohn's disease Exhibit 13: Crohn's disease: treatment pathway Exhibit 14: Ulcerative colitis: Symptoms Exhibit 15: Diagnostic approach for ulcerative colitis Exhibit 16: Treatment options for ulcerative colitis Exhibit 17: Surgical procedures to treat ulcerative colitis Exhibit 18: Crohn's disease: pipeline portfolio Exhibit 19: Crohn's disease clinical trial by phase Exhibit 20: Crohn's disease clinical trial by status Exhibit 21: Ulcerative colitis: pipeline portfolio Exhibit 22: Snapshot of global inflammatory bowel disease market 2014 Exhibit 23: Global inflammatory bowel disease market 2014-2019 ($ million) Exhibit 24: Inflammatory bowel disease market in US 2014-2019 ($ million) Exhibit 25: Inflammatory bowel disease market in EU 2014-2019 ($ million) Exhibit 26: Inflammatory bowel disease market in Japan 2014-2019 ($ million) Exhibit 27: Segmentation of global inflammatory bowel disease market by type of disease Exhibit 28: Segmentation of global inflammatory bowel disease market by type of disease 2014 Exhibit 29: Segmentation of global inflammatory bowel disease market by type of disease 2019 Exhibit 30: Revenue of global inflammatory bowel disease market 2014-2019 ($ million) Exhibit 31: Snapshot of global Crohn's disease market 2014 Exhibit 32: Global Crohn's disease market 2014-2019 ($ million) Exhibit 33: Crohn's disease market in US 2014-2019 ($ million) Exhibit 34: Crohn's disease market in Japan 2014-2019 ($ million)

Exhibit 35: Snapshot of global ulcerative colitis market Exhibit 36: Global ulcerative colitis market 2014-2019 ($ million) Exhibit 37: Segmentation of global inflammatory bowel disease market by drug class Exhibit 38: Benefits and risks of 5-ASA Exhibit 39: Segmentation of global inflammatory bowel disease market by drug class 2014 Exhibit 40: Segmentation of global inflammatory bowel disease market by type of molecule Exhibit 41: Segmentation of global inflammatory bowel disease market by type of molecule 2014 Exhibit 42: Segmentation of global inflammatory bowel disease market by dosage form Exhibit 43: Segmentation of global inflammatory bowel disease market by dosage form 2014 Exhibit 44: Segmentation of global inflammatory bowel disease market by route of administration Exhibit 45: Segmentation of global inflammatory bowel disease market by route of administration 2014 Exhibit 46: Segmentation of global inflammatory bowel disease market by geography 2014 Exhibit 47: Segmentation of global inflammatory bowel disease market by geography 2019 Exhibit 48: Segmentation of global Crohn's disease market by geography 2014 Exhibit 49: Segmentation of global ulcerative colitis market by geography 2014 Exhibit 50: Major drivers of global inflammatory bowel disease market Exhibit 51: Major challenges in global inflammatory bowel disease market Exhibit 52: Major trends in global inflammatory bowel disease market Exhibit 53: Ranking of vendors 2014 Exhibit 54: YoY revenue of top drugs for inflammatory bowel disease 2010-2014 ($ million) Exhibit 55: Revenue share of top drugs for inflammatory bowel disease 2010-2014 Exhibit 56: AbbVie: product portfolio Exhibit 57: YoY global revenue of Humira 2009-2014 ($ million) Exhibit 58: YoY revenue of Humira in US 2009-2014 ($ million) Exhibit 59: YoY international revenue of Humira (except US) 2009-2014 ($ million) Exhibit 60: Revenue comparison of Humira 2009-2014 ($ million) Exhibit 61: Janssen: product portfolio Exhibit 62: YoY global revenue of Remicade 2009-2014 ($ million) Exhibit 63: YoY global revenue of Simponi 2010-2014 ($ million) Exhibit 64: Merck: product portfolio Exhibit 65: YoY global revenue of Remicade 2009-2014 ($ million) Exhibit 66: YoY global revenue of Simponi 2010-2014 ($ million) Exhibit 67: Biogen Idec: product portfolio Exhibit 68: YoY global revenue of Tysabri 2009-2014 ($ million) Exhibit 69: YoY revenue of Tysabri in US 2009-2014 ($ million) Exhibit 70: YoY revenue of Tysabri in ROW 2009-2014 ($ million) Exhibit 71: Global revenue of Tysabri 2009-2014 ($ million) Exhibit 72: UCB: product portfolio Exhibit 73: YoY global revenue of Cimzia 2010-2014 ($ million) Exhibit 74: Shire: product portfolio Exhibit 75: YoY global revenue of Lialda 2010-2014 ($ million) Exhibit 76: AbbVie: product segmentation by revenue 2013 Exhibit 77: AbbVie: product segmentation by revenue 2012 and 2013 ($ million) Exhibit 78: AbbVie: sales by geography 2013 Exhibit 79: Biogen Idec: business segmentation by revenue 2013 Exhibit 80: Biogen Idec: geographical segmentation by revenue 2013 Exhibit 81: Merck: business segmentation by revenue 2013 Exhibit 82: Merck: business segmentation by revenue 2012 and 2013 ($ billion) Exhibit 83: Merck: sales by geography 2013 Exhibit 84: Shire: geographical segmentation by revenue 2013 Exhibit 85: UCB: product segmentation by revenue 2013 Exhibit 86: UCB: product segmentation by revenue 2012 and 2013 ($ million) Exhibit 87: UCB: geographical segmentation by revenue 2013

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3175853/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets,

Guinness Centre, Taylors Lane, Dublin 8, Ireland.

Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information Please verify that the product information is correct and select the format(s) you require. Product Name:

Global Inflammatory Bowel Disease Market 2015-2019

Web Address:

http://www.researchandmarkets.com/reports/3175853/

Office Code:

SC

Product Formats Please select the product formats and quantity you require: Quantity Electronic (PDF) Single User:

USD 3000

Electronic (PDF) 1 - 5 Users:

USD 3500

Electronic (PDF) Site License:

USD 4500

Electronic (PDF) Enterprisewide:

USD 10000

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information Please enter all the information below in BLOCK CAPITALS Title: First Name:

Mr

Mrs

Dr

Miss Last Name:

Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Ms

Prof

Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card:

You will receive an email with a link to a secure webpage to enter your credit card details.

Pay by check:

Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland.

Pay by wire transfer:

Please transfer funds to: Account number

833 130 83

Sort code

98-53-30

Swift code

ULSBIE2D

IBAN number

IE78ULSB98533083313083

Bank Address

Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World